ansuvimab sold brand name ebanga monoclonal antibody medication treatment zaire ebolavirus ebolavirus common symptoms include fever tachycardia fast heart rate diarrhea vomiting hypotension low blood pressure tachypnea fast breathing chills however also common symptoms ebolavirus ansuvimab approved medical use united states december world health organizations list essential drug composed single monoclonal antibody mab initially isolated immortalized bcells obtained survivor outbreak ebola virus disease kikwit democratic republic work supported united states national institutes health defense advanced projects agency heavy light chain sequences ansuvimab mab cloned cho cell lines initial production runs produced cook phamica dba catalent contract ansuvimab monoclonal antibody therapy infused intravenously patients ebola virus disease ansuvimab neutralizing meaning binds protein surface ebola virus required infect cells specifically ansuvimab neutralizes infection binding region ebola virus envelope glycoprotein absence ansuvimab would interact viruss cell receptor protein niemannpick competition ansuvimab prevents ebola virus binding neutralizes viruss ability infect targeted antibodies antigenbinding fragment fab regions constant fragment fc regions neutralization virus infection occurs fab regions antibodies binds virus antigens manner blocks infection antibodies also able kill virus particles directly andor kill infected cells using antibodymediated effector functions opsonization complementdependent cytotoxicity antibodydependent cellmediated cytotoxicity antibodydependent phagocytosis effector functions contained fc region antibodies also dependent binding fab region antigen effector functions also require use complement proteins serum fcreceptor cell membranes ansuvimab found capable killing cells antibodydependent cellmediated functional killing tests performedcitation needed ansuvimab monoclonal antibody evaluated treatment ebola virus discovery led laboratory nancy sullivan united states national institutes health vaccine research center j j muyembetamfum institut national pour la recherche biomedicale inrb democratic republic congo working collaboration institute research biomedicine irb bellinzona switzerland united states army medical research institute infectious ansuvimab isolated blood survivor outbreak ebola virus disease kikwit democratic republic congo roughly ten years phase clinical trial ansuvimab conducted martin gaudinski within vaccine research center clinical trials program led julie e ansuvimab also evaluated north kivu ebola ansuvimab also shown success lowering mortality rate august congolese health authorities world health organization us national institutes health promoted use ansuvimab alongside atoltivimabmaftivimabodesivimab similar regeneronproduced monoclonal antibody treatment treatments yielding higher mortality rates ending clinical trials us food drug administration fda approved ansuvimab based primarily evidence clinical trial trial nct participants zaire ebolavirus trial enrolled newborn pediatric adult participants including pregnant women zaire ebolavirus participants received standard supportive care addition standard care participants randomly assigned receive either onetime dose ansuvimab one three types experimental treatments including one control participants health care providers knew treatment trial conducted four sites democratic republic congo outbreak began august paper describes efforts ansuvimab originally developed part research efforts led dr nancy sullivan united states national institutes health vaccine research center dr j j muyembetamfum institut national de recherche biomedicale inrb democratic republic collaborative effort also involved researchers institute biomedical research united states army medical research institute infectious survivor outbreak ebola virus disease kikwit democratic republic congo donated blood project began roughly ten years memory b cells isolated survivors blood immortalized cultured screened ability produce monoclonal antibodies reacted glycoprotein ebola virus ansuvimab identified one cultures antibody heavy light chain gene sequences sequenced sequences cloned recombinant dna plasmids purified antibody protein initial studies produced cells derived hek experiment described paper rhesus macaques infected ebola virus treated combination ansuvimab another antibody isolated subject three doses combination given day starting day animals infected control animal died treated animals second experiment described paper rhesus macaques infected ebola virus treated ansuvimab three doses ansuvimab given day starting day days animals infected control animals died treated animals unpublished data referred publication phase clinical trial results ansuvimab reported single infusion ansuvimab provided full protection rhesus macaques basis dosing used human ansuvimab developed vaccine research center support united states national institutes health defense advanced projects agency heavy light chain sequences ansuvimab mab cloned cho cell lines enable largescale production antibody product use early phase clinical trial ansuvimabs safety tolerability pharmacokinetics conducted dr martin gaudinski within vaccine research center clinical trials program led dr julie e study performed united states nih clinical center tested single dose infusions ansuvimab infused minutes study showed ansuvimab safe minimal side effects halflife license ansuvimab obtained ridgeback biotherapeutics national institutes healthnational institute allergy infectious ansuvimab given orphan drug status may march équateur province ebola outbreak ansuvimab requested democratic republic congo drc ministry public health ansuvimab approved compassionate use world health organization meuri ethical protocol drc ethics board ansuvimab sent along therapeutic agents outbreak however outbreak came conclusion therapeutic agents given approximately one month following conclusion équateur province outbreak distinct outbreak noted kivu drc kivu ebola outbreak ansuvimab received approval compassionate use meuri drc ethic boards given many patients november pamoja tulinde maisha palm together save lives openlabel randomized clinical control trial begun multiple treatment units testing ansuvimab atoltivimabmaftivimabodesivimab remdesivir zmapp despite difficulty running clinical trial conflict zone investigators enrolled patients towards goal interim analysis data safety monitoring board dsmb first patient found ansuvimab superior comparator zmapp overall mortality patients zmapp remdesivir groups compared ansuvimab looking patients arrived early disease symptoms appeared survival ansuvimab study powered determine whether difference ansuvimab survival difference two therapies zmapp significant led dsmb halting study palm investigators dropping remdesivir zmapp arms clinical trial patients outbreak elect participate trial given either ansuvimab october us food drug administration fda approved atoltivimabmaftivimabodesivimab inmazeb formerly indication treatment infection caused zaire httpsenwikipediaorgwikiansuvimab